Cefepime Overdose Side Effects
Cefepime overdose primarily causes neurotoxicity, manifesting as encephalopathy (confusion, hallucinations, stupor, coma), myoclonus, seizures, and neuromuscular excitability, which can be fatal if not recognized and managed promptly 1.
Primary Neurological Manifestations
The neurotoxic effects of cefepime overdose result from its ability to cross the blood-brain barrier and antagonize GABA receptors in a concentration-dependent manner. The most common presentations include:
- Altered mental status (present in 100% of cases) 2
- Reduced consciousness (47% of cases) 2
- Myoclonus (42% of cases) 2
- Confusion and disorientation (42% of cases) 2
- Seizures and status epilepticus (including non-convulsive status epilepticus in 25% of cases) 2
- Aphasia 1
- Coma 1
Critical Concentration Thresholds
Cefepime trough concentrations above 22 mg/L (discontinuous infusions) or steady-state concentrations above 35 mg/L (continuous infusion) are associated with neurotoxicity in 50% of patients 3. Notably, cefepime has a relative pro-convulsive activity of 160 (compared to penicillin G = 100), making it significantly more neurotoxic than many other beta-lactams 3.
Key Risk Factors for Toxicity
The primary risk factor is renal impairment, which causes rapid drug accumulation 3. However, a critical finding from the literature review is that 48% of patients with neurotoxicity were overdosed according to FDA guidelines, but 26% experienced neurotoxicity despite appropriate renal dosing 2. This means neurotoxicity can occur even with correct dosing.
Additional risk factors include:
- Preexisting brain injury or blood-brain barrier dysfunction 2
- Depression or cancer (both associated with BBB impairment) 4
- Critical illness 2
- Elderly patients 5
- Elevated serum cefepime concentrations 2
Electroencephalographic Findings
When neurotoxicity is suspected, 98% of patients who undergo EEG will show abnormalities 2, including:
- Triphasic waves (40%)
- Non-convulsive status epilepticus (25%)
- Focal sharp waves (39%)
- Myoclonic status epilepticus (7%)
Clinical Course and Management
The median delay from drug initiation to symptom onset is 4 days, with resolution occurring a median of 2 days after intervention 2. Management includes:
- Immediate discontinuation of cefepime (primary intervention)
- Hemodialysis (recommended for removal in overdose, NOT peritoneal dialysis) 1
- Antiepileptic drug administration when seizures are present 2
- Supportive care with careful observation 1
Symptom improvement occurs in 89% of patients, with 87% surviving to hospital discharge 2, indicating generally good prognosis with appropriate recognition and intervention.
Critical Pitfall: Delayed Recognition
A particularly important finding is that cefepime-induced neurotoxicity occurred in 24% of overexposed patients when therapeutic drug monitoring results were obtained ≤48 hours, compared to 57.4% when results were delayed >48 hours 6. This emphasizes the critical importance of early therapeutic drug monitoring and dose adjustment.
Common Diagnostic Challenge
Cefepime-induced neurotoxicity is challenging to recognize in critically ill patients because the symptoms (altered mental status, confusion, seizures) are common in ICU patients from other causes 2. Maintain high clinical suspicion in any patient on cefepime who develops unexplained neurological deterioration, regardless of whether dosing appears appropriate for renal function 3.
Other Adverse Effects
Beyond neurotoxicity, overdose can cause:
- Anaphylaxis and anaphylactic shock 1
- Hematologic effects: transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia 1
- Positive Coombs' test (16.2% incidence) 1
The benefit-risk balance decreases significantly when free drug concentrations exceed eight times the MIC, as this threshold is associated with increased neurotoxicity without additional therapeutic benefit 3.